Wave 1 Trial Results For Cystic Fibrosis Therapy Delayed

The British Gene Therapy Consortium announced recently that it has decided not to attend the upcoming North American Cystic Fibrosis Conference (NACFC), where they were planning on presenting the latest data about their Multidose Gene Therapy (Wave 1) Trial, which focuses on developing a genetic treatment for cystic fibrosis (CF).

New Research Indicates 75% of Cystic Fibrosis Patients Exercise

A new study entitled “Self-reported exercise and longitudinal outcomes in cystic fibrosis: a retrospective cohort study” published in October issue of BMC Pulmonary Medicine suggests that self-reported exercise improves nutritional and pulmonary outcomes in adults with cystic fibrosis. Cystic Fibrosis is a life-threatening disease, characterized…

Novel Cystic Fibrosis Treatment Shows Promise Against Infections

Synedgen, Inc. will present recent study results on the successful application of the company’s novel polymer PAAG for treating Cystic Fibrosis. The data is compiled in two posters entitled “PAAG decreases viscosity and Improves Transportability of Cystic Fibrosis Mucus In Situ” and “Novel Biopolymer Mucolytic PAAG Prevents and Treats Biofilms…

RPL554 Emerging As Viable Cystic Fibrosis Therapy

Data supporting a promising, new treatment for Cystic Fibrosis (CF) developed by Verona Pharma will be presented for the first time at the 28th Annual North American Cystic Fibrosis Conference (NACFC) in Atlanta, Georgia on October 9-11, 2014. Verona Pharma’s key molecule, RPL554, is currently being evaluated in a…